secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2022-01-04T23:59:59+00:00
Accession:  0001628280-22-000142
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion appoints Benjamin O. Looker as General Counsel effective Jan 1, 2022
-----------------------------------------------------------------------------

- Appointed Benjamin O. Looker as General Counsel effective Jan 1, 2022, reporting to CEO Sheldon Koenig.
- Looker previously served as GC of Trillium Therapeutics until its acquisition by Pfizer in Nov 2021.
- Compensation includes $375k base salary, 40% target bonus, option for 100,450 shares, and 70,800 RSUs.
- Looker will lead legal, compliance, and ethics operations, with focus on upcoming CLEAR Outcomes trial results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828022000142/0001628280-22-000142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828022000142/espr-20220104.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-000142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer